首届检验医学科普菁英大赛入围稿件作者：黄伟单位：广东阳春市中医院前言输血是医疗中用于补充血容量、提高氧气携带能力、提供凝血因子和免疫球蛋白等的重要手段。它可以帮助治疗失血过多、贫血、凝血障碍和某些免疫缺陷。在紧急情况下，输血能迅速稳定患者的生命体征， ...

A single-center retrospective study found the approval and use of new agents to treat chronic graft-versus-host disease (GVHD ...

Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option for patients with ...

2024年10月16日，专注于肿瘤和自免疾病通用型γδT细胞疗法的上市公司Adicet ...

11月4日，Royalty Pharma和Syndax Pharmaceuticals共同宣布，双方达成一项价值 3.5 亿美元的合成专利费融资协议，该协议基于Niktimvo （axatilimab-csfr） 在美国的净销售额。

马萨诸塞州沃尔瑟姆 - Syndax制药公司（纳斯达克股票代码：SNDX）与Royalty ...

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder. The US regulator has cleared ...

A new study finds that eliminating radiation from conditioning regimens in patients with dyskeratosis congenita undergoing ...

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

Additionally, in August, the FDA approved Niktimvo™ (axatilimab-csfr) for patients with chronic graft-versus-host disease, ...